Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 38.8%

Oculis Holding AG (NASDAQ:OCS) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 34,700 shares, a growth of 38.8% from the February 28th total of 25,000 shares. Based on an average daily volume of 71,500 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Bellevue Group AG acquired a new stake in shares of Oculis during the 4th quarter worth about $170,000. XTX Topco Ltd acquired a new position in Oculis in the fourth quarter valued at about $225,000. Geode Capital Management LLC boosted its stake in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Oculis during the fourth quarter valued at about $389,000. Finally, Bank of America Corp DE raised its stake in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after acquiring an additional 10,667 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. HC Wainwright dropped their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Robert W. Baird boosted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price target on shares of Oculis in a report on Thursday, March 13th.

Oculis Price Performance

Oculis stock opened at $19.18 on Monday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $20.66 and a 200 day moving average price of $17.52. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08. The stock has a market cap of $837.44 million, a P/E ratio of -9.94 and a beta of 0.01.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Sell-side analysts anticipate that Oculis will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.